Literature DB >> 16412031

Pathogenesis of nonalcoholic steatohepatitis (NASH).

Xiong Ma1, Zhiping Li.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver diseases that range from hepatic steatosis at the most clinically benign end of the spectrum, through an intermediate lesion, nonalcoholic steatohepatitis (NASH), to cirrhosis at the opposite extreme. Epidemiology studies have estimated that about 20-30% of adults in the United States and other Western countries have NAFLD, and of these about 10% (2-3% of adults) meet the diagnostic criteria of NASH. Studies of animals and humans with obesity-related fatty liver disease have revealed much about the mechanisms that mediate this common pathology. The pathogenesis of NASH is multifactorial and includes insulin resistance, excessive intracellular fatty acids, oxidant stress, mitochondrial dysfunction and the role of innate immunity. This review will briefly discuss the epidemiology of NAFLD and focus on current understanding of the pathogenesis of NASH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412031     DOI: 10.1111/j.1443-9573.2006.00237.x

Source DB:  PubMed          Journal:  Chin J Dig Dis        ISSN: 1443-9573


  8 in total

1.  Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.

Authors:  Y Tang; Z Bian; L Zhao; Y Liu; S Liang; Q Wang; X Han; Y Peng; X Chen; L Shen; D Qiu; Z Li; X Ma
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

2.  Coexistence of hyperlipidemia and acute cerebral ischemia/reperfusion induces severe liver damage in a rat model.

Authors:  Wei-Hong Gong; Wen-Xia Zheng; Jun Wang; Shi-Hui Chen; Bo Pang; Xia-Min Hu; Xiao-Lu Cao
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

3.  Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Authors:  Feng-Shang Zhu; Su Liu; Xi-Mei Chen; Zhi-Gang Huang; Dong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

4.  Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease.

Authors:  Sahar Saad El-Din Bessa; Ehab Mostafa Mohamed Ali; Abeer El-Sayed Abd El-Wahab; Sherif Abd El-Monem Nor El-Din
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

Review 5.  Therapeutic Potential of HNF4α in End-stage Liver Disease.

Authors:  Ricardo Diaz-Aragon; Michael C Coard; Sriram Amirneni; Lanuza Faccioli; Nils Haep; Michelle R Malizio; Takashi Motomura; Zehra N Kocas-Kilicarslan; Alina Ostrowska; Rodrigo M Florentino; Carla Frau
Journal:  Organogenesis       Date:  2021-10-02       Impact factor: 2.316

6.  Histological, Immunohistochemical, and Biochemical Study of Experimentally Induced Fatty Liver in Adult Male Albino Rat and the Possible Protective Role of Pomegranate.

Authors:  Nadia F Hassan; Gehan M Soliman; Ebtsam F Okasha; Amany M Shalaby
Journal:  J Microsc Ultrastruct       Date:  2018 Jan-Mar

7.  Albino mice with the point mutation at the tyrosinase locus show high cholesterol diet-induced NASH susceptibility.

Authors:  Kaushalya Kulathunga; Arata Wakimoto; Yukiko Hiraishi; Manoj Kumar Yadav; Kyle Gentleman; Eiji Warabi; Tomoki Sakasai; Yoshihiro Miwa; Seiya Mizuno; Satoru Takahashi; Michito Hamada
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

8.  Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism.

Authors:  Yida Zhang; Susan S Baker; Robert D Baker; Ruixin Zhu; Lixin Zhu
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.